Alkermes (ALKS)
46.10
-0.78 (1.66%)
Upcoming Events
Latest Headlines
Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
September 1, 2026 3:55 AM - StreetInsider
Alkermes narcolepsy drug data published in The Lancet Neurology
August 24, 2026 6:30 PM - StreetInsider
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
August 24, 2026 6:30 PM - BizWire
Form 4 Alkermes plc. For: Aug 17 Filed by: Nichols Christian Todd
August 17, 2026 6:54 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Nichols Christian Todd
August 17, 2026 4:50 PM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: snyderman nancy lynn MD
August 12, 2026 11:03 AM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: Hopkinson Craig C.
August 12, 2026 11:03 AM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: Gaffin David Joseph
August 12, 2026 11:03 AM - SEC Filing
Form 8-K Alkermes plc. For: Aug 12
August 12, 2026 9:27 AM - SEC Filing
Form 4 Alkermes plc. For: Aug 05 Filed by: Jackson Blair Curtis
August 7, 2026 9:17 PM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: snyderman nancy lynn MD
August 3, 2026 7:17 PM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: Hopkinson Craig C.
August 3, 2026 7:13 PM - SEC Filing
Form 4 Alkermes plc. For: Aug 03 Filed by: Gaffin David Joseph
August 3, 2026 7:09 PM - SEC Filing
Form 144 Alkermes plc. Filed by: snyderman nancy lynn MD
August 3, 2026 4:34 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Gaffin David Joseph
August 3, 2026 4:32 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Hopkinson Craig C.
August 3, 2026 4:32 PM - SEC Filing
Form 8-K/A Alkermes plc. For: Feb 24
August 3, 2026 4:09 PM - SEC Filing
Weakness in this biotech stock is a buying opportunity: Mizuho
July 31, 2026 9:00 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
July 30, 2026 6:51 AM - StreetInsider
Alkermes (ALKS) PT Raised to $61 at JPMorgan
July 29, 2026 8:28 AM - StreetInsider
Alkermes (ALKS) PT Raised to $58 at Baird
July 29, 2026 6:38 AM - StreetInsider
Form S-8 Alkermes plc.
July 28, 2026 4:55 PM - SEC Filing
Form 10-Q Alkermes plc. For: Jun 30
July 28, 2026 9:23 AM - SEC Filing
Alkermes (ALKS) PT Raised to $65 at Piper Sandler
July 28, 2026 7:13 AM - StreetInsider
Alkermes (ALKS) Tops Q2 EPS by 2c; updates guidance
July 28, 2026 7:10 AM - StreetInsider
Form 8-K Alkermes plc. For: Jul 28
July 28, 2026 7:05 AM - SEC Filing
Alkermes plc Reports Second Quarter 2026 Financial Results
July 28, 2026 7:00 AM - BizWire
Alkermes (ALKS) PT Raised to $63 at Stifel
July 20, 2026 5:14 AM - StreetInsider
Alkermes to Report Second Quarter Financial Results on July 28, 2026
July 14, 2026 4:00 PM - BizWire
Alkermes (ALKS) PT Raised to $57 at TD Cowen
July 13, 2026 9:20 AM - StreetInsider
Alkermes drug shows sustained narcolepsy benefits at nine months
July 13, 2026 7:01 AM - StreetInsider
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
July 13, 2026 7:00 AM - BizWire
JPMorgan Resumes Alkermes (ALKS) at Neutral
July 13, 2026 3:13 AM - StreetInsider
Alkermes terminates authorized generic supply deal with Amneal
July 8, 2026 8:10 AM - StreetInsider
Form 8-K Alkermes plc. For: Jul 06
July 8, 2026 8:00 AM - SEC Filing
Form 4 Alkermes plc. For: Jul 06 Filed by: Gaffin David Joseph
July 6, 2026 4:48 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Gaffin David Joseph
July 6, 2026 4:18 PM - SEC Filing
Alkermes (ALKS) PT Raised to $65 at Mizuho
July 2, 2026 5:04 AM - StreetInsider
Form 4 Alkermes plc. For: Jul 01 Filed by: Hopkinson Craig C.
July 1, 2026 6:29 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Hopkinson Craig C.
July 1, 2026 4:13 PM - SEC Filing
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
June 29, 2026 11:51 AM - StreetInsider
Alkermes (ALKS) PT Raised to $65 at Wells Fargo
June 29, 2026 6:33 AM - StreetInsider
BofA Securities Downgrades Alkermes (ALKS) to Underperform
June 29, 2026 6:05 AM - StreetInsider
Alkermes (ALKS) PT Raised to $61 at Needham
June 24, 2026 7:11 AM - StreetInsider
Alkermes (ALKS) PT Raised to $50 at TD Cowen
June 22, 2026 8:26 AM - StreetInsider
Alkermes (ALKS) PT Raised to $54 at Needham
June 18, 2026 7:05 AM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
June 18, 2026 6:43 AM - StreetInsider
Alkermes narcolepsy drug meets phase 2 trial endpoints
June 17, 2026 4:15 PM - StreetInsider
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 17, 2026 4:15 PM - BizWire
Form 8-K Alkermes plc. For: Jun 15
June 15, 2026 7:10 AM - SEC Filing
Alkermes receives orphan drug status for alixorexton in U.S. and Europe
June 15, 2026 7:02 AM - StreetInsider
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 15, 2026 7:00 AM - BizWire
Form 4 Alkermes plc. For: Jun 12 Filed by: Wright Christopher I
June 12, 2026 8:04 PM - SEC Filing
Form 144 Alkermes plc. Filed by: Wright Christopher I
June 12, 2026 4:19 PM - SEC Filing
Alkermes (ALKS) PT Raised to $56 at RBC Capital; 'Don't Sleep On The Pipeline'
June 9, 2026 7:33 AM - StreetInsider
Full Article List
